

No data available
No data available
No data available
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 92.20 | 232.70 | 119.97 | 95.70 | 71.17 |
| Total Expenses | 91.04 | 230.44 | 118.80 | 94.60 | 70.89 |
| Profit Before Tax | 1.17 | 2.26 | 1.16 | 1.10 | 0.28 |
| Profit After Tax | 0.86 | 1.53 | 0.91 | 0.80 | 0.19 |
| Operating Profit After Depreciation | 3.11 | 3.65 | 3.35 | 4.19 | 3.97 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 2.62 | 2.52 | 0.73 | 0.47 | 0.42 |
| Total Non Current Assets | 4.08 | 3.89 | 2.49 | 1.74 | 1.77 |
| Total Current Assets | 97.45 | 97.92 | 58.09 | 70.73 | 70.01 |
| Total Assets | 101.53 | 101.80 | 60.58 | 72.46 | 71.78 |
| Total Shareholder's Fund | 29.97 | 29.01 | 27.48 | 26.68 | 25.88 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | -5.58 | 6.18 | 5.26 | 12.40 | 8.33 |
| Net Cash Used In Investing Activities | -1.23 | -1.85 | -0.06 | 0.09 | 0.12 |
| Net Cash Used In Financing Activities | 2.19 | -5.80 | -4.45 | -9.62 | -6.42 |
No data available
No data available
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,763.70 | ₹4,23,170.71 |
| Divis Laboratories Ltd | ₹6,523.25 | ₹1,73,171.79 |
| Torrent Pharmaceuticals Ltd | ₹3,816.75 | ₹1,29,170.36 |
| Cipla Ltd | ₹1,536.25 | ₹1,24,093.85 |
| Dr Reddys Laboratories Ltd | ₹1,244.50 | ₹1,03,868.61 |
No data available
On 13 November 2025
08 Nov 2025, 04:59 pm
On 30 September 2025
17 Sep 2025, 02:12 pm
On 29 May 2025
26 May 2025, 06:43 pm

Get started with us today and
start building your wealth journey
*By clicking, I agree to the T&C and Whatsapp updates.

Get started with us today and
start building your wealth journey
*By clicking, I agree to the T&C and Whatsapp updates.

Congratulations,
Your Digital savings bank account opening journey is complete.